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Summary
 
Large numbers of neuritic plaques (NP), largely composed of a fibrillar insoluble form of the
 
b
 
-amyloid peptide (A
 
b
 
), are found in the hippocampus and neocortex of Alzheimer’s disease
(AD) patients in association with damaged neuronal processes, increased numbers of activated
astrocytes and microglia, and several proteins including the components of the proinflamma-
tory complement system. These studies address the hypothesis that the activated complement
system mediates the cellular changes that surround fibrillar A
 
b
 
 deposits in NP. We report that
A
 
b
 
 peptides directly and independently activate the alternative complement pathway as well as
the classical complement pathway; trigger the formation of covalent, ester-linked complexes of
A
 
b
 
 with activation products of the third complement component (C3); generate the cytokine-
like C5a complement-activation fragment; and mediate formation of the proinflammatory
C5b-9 membrane attack complex, in functionally active form able to insert into and permeabi-
lize the membrane of neuronal precursor cells. These findings provide inflammation-based
mechanisms to account for the presence of complement components in NP in association with
damaged neurons and increased numbers of activated glial cells, and they have potential impli-
cations for the therapy of AD.
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W
 
e and others (1–3) have noted that the patholog-
ical changes which characterize Alzheimer’s disease
(AD)
 
1
 
 could all result from complement activation in neu-
ritic plaques (NP), since this effector system has the ability
to activate various cell types with release of cytokines and
secondary mediators; to induce directed migration of these
cells toward the complement activator; to alter cellular
functions; and to damage cells (4, 5). Potential complement
involvement in the brain is not dependent on disruption of
the blood–brain barrier, since neurons, astrocytes, micro-
glia, and oligodendrocytes synthesize most, and likely all, of
the proteins of the complement system (6).
Since activation is a prerequisite for manifestation of all
of the biological activities of the complement system, the
 
b
 
-amyloid peptide (A
 
b
 
) or another component of NP
must possess the ability to activate complement in order for
complement to be involved in mediating the pathologic
cellular characteristics of AD. In this regard, we and others
previously showed that fibrillar forms of A
 
b
 
 bound the first
reacting factor of the classical complement pathway (CCP),
C1q (3, 7), and depleted the activity of the fourth comple-
ment component (C4) as well as whole complement activ-
ity (CH50), when incubated with human serum as a com-
plement source in vitro (3, 7). Residues 14–26 of the
collagen-like portion of the A polypeptide chain of the
C1q molecule were implicated in binding fibrillar A
 
b
 
 (7).
Recent studies have confirmed this suggestive evidence of
CCP activation by aggregated A
 
b
 
 (8–12), and have also
emphasized the critical role of the 
 
b
 
-pleated structure of
A
 
b
 
 in mediating these effects (9, 11). Inhibition studies
have implicated A
 
b
 
 residues 1–11 in C1q binding (11, 12).
The complement depletion, inhibition, and cleavage assays
used in these various studies have provided suggestive evi-
dence for CCP activation by fibrillar A
 
b
 
; however, as indi-
rect assays, they are subject to other interpretations. In this
context, we recently presented preliminary evidence sug-
gesting that A
 
b
 
 forms complexes with C3 after incubation
of fibrillar A
 
b
 
 with a complement source (9).
In the course of these studies, we found that the addition
of fibrillar A
 
b
 
 to a complement source led to the genera-
tion of covalent ester-linked complexes of A
 
b
 
 with C3 ac-
tivation fragments, providing unequivocal evidence for
complement activation by A
 
b
 
, since covalent attachment
 
1
 
Abbreviations used in this paper:
 
 ACP, alternative complement pathway;
AD, Alzheimer’s disease; A
 
b
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b
 
-amyloid peptide; CCP, classical comple-
ment pathway; dd, double distilled; MAC, membrane attack complex;
NP, neuritic plaques; NHS, normal human serum; SOD, superoxide dis-
mutase.
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of C3 activation fragments to complement activators repre-
sents a fundamental tenet of complement action. We also
found that fibrillar A
 
b
 
 possesses the ability to activate the
alternative complement pathway (ACP) in serum, as well as
in mixtures of the six purified proteins of the alternative
pathway in physiologic concentrations, providing the first
indication that A
 
b
 
 independently activates both comple-
ment pathways. Additionally, we observed that such activa-
tion is highly specific for A
 
b
 
 and completely independent
of oxidative processes. These studies are described here. Fi-
nally, we also report for the first time that A
 
b
 
-mediated
complement activation is biologically significant, as it leads
to generation of the cytokine-like C5a complement-activa-
tion fragment, and mediates formation of the proinflamma-
tory C5b-9 membrane attack complex (MAC), in func-
tionally active form able to insert into and permeabilize the
membranes of neuronal precursor cells.
 
Materials and Methods
 
A
 
b
 
-Mediated Complement Activation and Complement Activation
ELISA Assays.
 
A
 
b
 
 1–40 and 1–42 (Bachem California, Tor-
rance, CA; Bachem Bioscience, Inc., King of Prussia, PA; Qual-
ity Controlled Biochemicals, Inc., Hopkinton, MA; Anaspec,
Inc., San Jose, CA; and California Peptide Research, Inc., Napa,
CA) were dissolved in either 100% DMSO at 10 mg/ml, or double
distilled (dd)H
 
2
 
O, gradually diluted in ddH
 
2
 
O to 2 mg/ml and
then brought to 1 mg/ml in 0.1 M Tris buffer, pH 7.4. A
 
b
 
 was
used immediately (nonaggregated) or permitted to aggregate by
incubation at room temperature for 48 h (A
 
b
 
 1–42) to 72 h (A
 
b
 
1–40); further incubation for 2 wk did not decrease complement-
activating potential. Preaggregated A
 
b
 
 preparations were incu-
bated with an equal volume of 1:5 normal human serum (NHS),
complement-depleted sera (Advanced Research Technologies,
Inc.), or the six purified proteins of the ACP (Advanced Research
Technologies, Inc.) in physiologic ratios (13). Dilutions were in
veronal buffered saline, pH 7.4, containing calcium and magne-
sium. Inhibition studies were carried out with preaggregated A
 
b
 
1–42 in the presence of deferoxamine, glutathione, dimethylthio-
urea, catalase, or superoxide dismutase (SOD), all purchased from
Sigma Chemical Co. (St. Louis, MO). After 1 h at 37
 
8
 
C, EDTA
was added to stop further complement activation, and the samples
were diluted (1:20–1:300) and added, in replicate, to microtitra-
tion wells precoated overnight (4
 
8
 
C) with 1 
 
m
 
g (100 
 
m
 
l) of mAb
to A
 
b
 
 (10D5), mAb to a C3b neoantigen (clone 129), or mAb to
an iC3b neoantigen (Quidel, San Diego, CA) at pH 7.4, and then
blocked (BLOTTO; Pierce Chemical Co., Rockford, IL). After
1 h at room temperature, bound A
 
b
 
–C3b/iC3b complexes were
detected with rabbit Ab to C3 or to A
 
b
 
, horseradish peroxidase–
conjugated anti–rabbit IgG (Kirkegaard & Perry Laboratories,
Gaithersburg, MD), and ABTS (Kirkegaard & Perry Laborato-
ries). C3 standard curves were generated with dilutions of puri-
fied iC3b (Advanced Research Technologies, Inc.) captured on
wells precoated with anti-iC3b (Quidel). C5b-9 was captured on
wells precoated with mAb to a C5b-9 neoantigen located in the
poly C9 portion of the complex (Quidel) and detected with poly-
clonal goat Ab to C6 followed by horseradish peroxidase–conju-
gated mouse anti–goat IgG (Accurate Chemical and Science
Corp., Westbury, NY) and ABTS. Values for the C5b-9 assay
were back-calculated to the values in undiluted NHS. In some
experiments, neuropeptide Y-porcine, urotensin I, or exendin 3
(all from California Peptide Research, Inc.); insulin B chain
(Sigma Chemical Co.); amyloid precursor protein peptide (657–
676 (Bachem California); and adenovirus penton base 50-residue
fragment (residues 317–366; reference 14), as well as preaggre-
gated A
 
b
 
 1–42 preparations and monomeric A
 
b
 
 1–42, were dis-
solved in DMSO or ddH
 
2
 
O and aged at room temperature, ex-
actly as described above for A
 
b
 
. In some studies, peptides, after
dissolution as just described but diluted in Hepes-buffered NaCl
at pH 7.4, were covalently cross-linked at a concentration of 200
 
m
 
M with the primary amine reactive agent, bis(sulfosuccinimi-
dyl)suberate (BS
 
3
 
; Pierce Chemical Co.), at a concentration of
5 mM. After 30 min, the reaction was terminated by quenching.
All peptides were incubated with NHS for 1 h at 37
 
8
 
C. After di-
lution, complement activation was assessed by the conventional
CH50 assay (15) by quantitating residual functional C3 using C3-
depleted serum according to product instructions (Advanced Re-
search Technologies, Inc.), or by evaluating C5b-9 formation.
 
Studies with Hydroxylamine.
 
After capture of complexes onto
10D5-coated wells, replicate wells were treated with 0.1 M Tris,
pH 9.5, or 1 M hydroxylamine in 0.1 M Tris, pH 9.5, for 2 h at
37
 
8
 
C. After washing, remaining bound C3 was detected as de-
scribed above. Residual A
 
b
 
 was detected with rabbit Ab to A
 
b
 
,
as described above. The formation of covalent complexes of A
 
b
 
with C3 activation products was also evaluated using the Western
blotting procedure on SDS-PAGE gels. Replicate samples of ag-
gregated A
 
b
 
 1–42 or A
 
b
 
 1–40 were incubated with human se-
rum for 1 h at 37
 
8
 
C in the presence or absence of EDTA, and the
reaction mixtures were then microfuged, washed in Tris buffer,
and incubated for 3 h at 37
 
8
 
C with 0.1 M Tris at pH 7.4, 0.1 M
Tris at pH 9.5, or 1 M hydroxylamine in 0.1 M Tris at pH 9.5.
The samples were again microfuged, and washed with Tris at pH
7.4 followed by the same buffer containing 0.1% SDS. The sam-
ples were then subjected to SDS-PAGE under nonreducing con-
ditions and electroblotted, and bands were detected with rabbit
Ab to C3 followed by goat anti–rabbit IgG (Kirkegaard & Perry
Laboratories) and the SuperSignal system (Pierce Chemical Co.).
After stripping, A
 
b
 
 was detected with 6E10 mouse Ab to A
 
b
 
(Senetek PLC, St. Louis, MO) followed by goat anti–mouse IgG
(Kirkegaard & Perry Laboratories) and the SuperSignal system. In
some experiments, electroblotted gels were reacted first with rab-
bit Ab to A
 
b
 
 (generated in this laboratory) or with 6E10 mAb to
A
 
b
 
 (Senetek PLC) followed by goat anti–rabbit IgG (Kirkegaard
& Perry Laboratories) or goat anti–mouse IgG (Kirkegaard &
Perry Laboratories), stripped, and reacted with mAb anti-iC3b
(Quidel) or rabbit Ab to C3 (generated in this laboratory), fol-
lowed by goat anti–mouse IgG or goat anti–rabbit IgG. Quantita-
tion was with a PhosphorImager (Molecular Dynamics, Sunny-
vale, CA).
 
Mass Spectroscopy.
 
After solubilization in 70% formic acid,
samples were analyzed by MALDI spectroscopy (Perseptive Voy-
ager ELITE; Perseptive Biosystems, Inc., Framingham, MA).
 
C5a.
 
C5a (and C5a des-Arg) was detected in diluted samples
with the Biotrak radioimmunoassay kit (Amersham Corp., Ar-
lington Heights, IL); the samples were subjected to acid precipita-
tion before analysis (16). Values were back-calculated to the con-
centrations in undiluted NHS.
 
C5b-9 Membrane Insertion.
 
Ntera2/D1 (NT2) cells (Stratagene
Inc., La Jolla, CA) were grown to subconfluence, released with
nonenzymatic cell dissociation solution (GIBCO BRL, Gaithers-
burg, MD), washed, and resuspended (2 
 
3
 
 10
 
7
 
 cells/ml). NT2
cells (100 
 
m
 
l) were incubated with 50 
 
m
 
l NHS in the presence or
absence of EDTA and 50 
 
m
 
l preaggregated A
 
b
 
. After 15 min at
37
 
8
 
C, the MAC was detected with rabbit Ab (Advanced Re- 
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search Technologies, Inc.) or mAb (Quidel) to C5b-9 neoanti-
gens, followed by FITC anti–rabbit or –mouse Ig and propidium
iodide. Readings were performed on a FACScan
 
Ò
 
 and analyzed
with CellQuest software (Becton Dickinson, San Jose, CA).
 
Results and Discussion
 
Sandwich-type ELISAs showed that complexes contain-
ing A
 
b
 
 and C3b/iC3b were generated in NHS, as a comple-
ment source, after incubation with aggregated A
 
b
 
 1–42.
Complexes were demonstrable after capture with mAbs to
activation-dependent neoantigens in the first (C3b) or sec-
ond (iC3b) C3 cleavage products and detection with rabbit
Ab to A
 
b
 
 (Fig. 1, 
 
a
 
 and 
 
b
 
), as well as after capture with mAb
to A
 
b 
 
and detection with rabbit Ab to C3 (Fig. 1 
 
c
 
) or C3d
(not shown). EDTA, which blocks complement activation
by chelating calcium and magnesium, prevented complex
formation (Fig. 1 
 
c
 
). ELISAs in which complexes were cap-
tured with mAb to A
 
b 
 
and detected with Ab to C3 were used
for most of the studies, since such ELISAs permitted quantita-
tion by reference to included standard curves generated with
purified C3 captured on wells coated with mAb to C3 and de-
tected with rabbit Ab to C3 (Fig. 1 
 
d
 
). Complement activation
was detectable to 
 
z
 
1 
 
m
 
M A
 
b
 
 1–42 (Fig. 1 
 
d
 
). 10 different
preaggregated A
 
b
 
 1–40 and 20 different preaggregated A
 
b
 
1–42 preparations from 5 manufacturers generated such
complexes. A
 
b
 
 1–42 was generally 5–10-fold more active
than A
 
b
 
 1–40 in this regard. The cation-dependent forma-
tion of A
 
b
 
–C3b/iC3b complexes after incubation of aggre-
gated A
 
b
 
 with NHS provides unequivocal evidence for
complement activation by aggregated A
 
b
 
.
A
 
b
 
–C3b/iC3b complex formation was evident after in-
cubation of aggregated A
 
b
 
 1–42 with NHS lacking factor
B, an essential component of the ACP (Fig. 1 
 
e); such sera
contain an intact CCP, but do not permit ACP activation.
A significant reduction in complex formation was also evi-
dent in C1q-depleted serum compared with NHS (Fig. 1 e).
These data show that the CCP mediates complex forma-
tion by aggregated Ab, findings that were anticipated from
the results of the complement depletion assays described
earlier. Unexpectedly, however, the ACP also mediated
the formation of complexes, since they were also generated
after the addition of aggregated Ab 1–42 to NHS lacking
factor C1q, and complex formation was reduced in factor
B–depleted serum compared with NHS (Fig. 1 e), a result
replicated in four additional experiments with different Ab
1–42 preparations. The ability of Ab 1–42 to activate the
ACP was confirmed in three studies in which preaggregated
Ab 1–42 was incubated with a mixture of the six purified
proteins of the ACP (factors B, D, H, and I, properdin, and
C3) in physiological ratios (reference 13; Fig. 1 f ). These
data document the ability of aggregated Ab not only to acti-
vate the CCP, but also to independently activate the ACP.
This is the first indication that aggregated Ab activates the
ACP; it had been presumed that complement activation by
Ab was exclusively via the CCP because of the absence of
ACP components (factor B and properdin) in NP (1, 17,
18). The failure to detect ACP components in NP may be
due to the extreme lability of the ACP C3 convertase.
Multiple different aggregated Ab 1–42 preparations acti-
vated complement, as determined by the classical CH50
complement consumption technique (Fig. 1 g). The aging
Figure 1. ELISA demonstra-
tion of complement-mediated
formation of complexes of Ab
with C3 activation fragments (a–
d). Complexes were captured,
detected, and quantitated as de-
scribed in Materials and Meth-
ods. NHS or purified ACP pro-
teins only do not contain Ab. (a)
Preaggregated Ab 1–42 (100
mM and 50 mM) was incubated
in NHS, captured with mAb to
C3b, and detected with rabbit
Ab to Ab. (b) Two preaggre-
gated Ab 1–42 preparations (Ab
1 and Ab 2, at 20 mM) were in-
cubated in NHS, captured with
mAb to iC3b, and detected with
rabbit Ab to Ab. (c) Preaggre-
gated Ab 1–42 (58 mM) was in-
cubated in NHS, or in NHS
containing 10 mM EDTA, cap-
tured with mAb to Ab, and de-
tected with rabbit Ab to C3. (d) Preaggregated Ab 1–42 was incubated in NHS at the indicated final concentrations, captured with mAb to Ab, and
detected with rabbit Ab to C3. (e) Preaggregated Ab 1–42 (58 mM) was incubated in NHS, factor B–depleted NHS (B-dpl), or C1q-depleted NHS
(C1q-dpl), captured with mAb to Ab, and detected with rabbit Ab to C3. (f ) Preaggregated Ab 1–42 (58 mM) was incubated with the six purified ACP
proteins (PAP) or NHS, captured with mAb to Ab, and detected with rabbit Ab to C3. Background levels obtained in EDTA controls containing Ab
and purified ACP proteins or NHS, in the various experiments described above, were subtracted. (g) Specificity of complement activation. Preaggregated
Ab preparations (20 mM) and the same concentrations of monomeric Ab (mono), insulin B chain (Ins.B), neuropeptide Y-porcine (NPY), urotensin I
(Uro.), exendin 3 (Exen), amyloid precursor peptide 657–676 (APP-pep.), and adenovirus penton base 50-residue peptide (PB50) were incubated with
NHS. Complement activation was assessed by the CH50 method. Correlation coefficients for the CH50 determinations ranged from 0.995 to 1.000.434 Complement and Alzheimer’s Disease
procedure used to aggregate Ab generates b-pleated fibrils
(9). Nonfibrillar “amorphous” aggregates of Ab are devoid
of complement-activating ability (9). In contrast to the ag-
gregated preparations, Ab used immediately after dissolu-
tion had limited ability to activate complement (Fig. 1 g).
These data document the important role of fibril formation
for complement activation by Ab in vitro. Amylin, another
peptide which spontaneously forms b-pleated fibrils, was
also tested for complement-activating ability in these stud-
ies. The 37-residue amylin polypeptide represents the prin-
cipal constituent of the amyloid deposits in type 2 diabetes.
On SDS-PAGE gels, aged amylin migrated primarily as
large SDS-insoluble stained bands. However, this fibrillar
peptide did not significantly activate complement at a con-
centration of 100 mM (7% CH50 consumption).
The specificity of complement activation by Ab was also
evaluated by determining whether complement was acti-
vated by other small peptides (20–50 amino acids) contain-
ing multiple residues able to mediate covalent linkage to
the glutamate residue of the hydrolyzed thioester of C3
(serine, tyrosine, threonine, lysine) and expressing similar
overall charge to Ab. All of the peptides were processed
and aged in the same manner as Ab. None of the peptides,
including the insulin B chain (30 residues), neuropeptide
Y-porcine (36 residues), urotensin I (41 residues), exendin
3 (39 residues), amyloid precursor peptide 657–676 (20 res-
idues), and the adenovirus penton base fragment (50 resi-
dues) significantly activated complement at a concentration
of 20 mM, as assessed by the classical CH50 technique (Fig.
1 g). The peptides also showed little or no ability to activate
complement in other assays, including the ability to deplete
residual functional C3 and form the SC5b-9 complex (not
shown). To determine whether peptide aggregation would
increase complement-activating ability, urotensin I, neu-
ropeptide Y-porcine, and exendin 3 were covalently cross-
linked with the primary amine reactive reagent BS3 before
evaluating their ability to activate complement by the
CH50 technique. Cross-linked urotensin I and neuropep-
tide Y-porcine gave a ladder of Coomassie-stained bands
on SDS-PAGE analyses, but exendin 3 gave no stained
bands, possibly due to the formation of very large aggregates.
These three cross-linked peptides did not significantly acti-
vate complement (,10% CH50 depletion) at a concentra-
tion of 20 mM. In another study, cross-linked urotensin I ex-
hibited 7% CH50 consumption at a concentration of 100
mM, whereas aggregated Ab 1–42 showed 45% consump-
tion. These data cumulatively demonstrate the marked spec-
ificity of complement activation by fibrillar Ab.
C3 preferentially binds to activators via ester bonds, al-
though amide linkage has been described (19, 20); such
bonds form between the reactive g-carbonyl group of the
glutamate residue of the activation-cleaved internal thioester
bond in C3, and hydroxyl (ester) or amino (amide) groups
on the activator (19). To evaluate possible ester linkage,
complexes were captured with mAb to Ab and incubated
with Tris buffer containing 1 M hydroxylamine at pH 9.5
for 2 h at 378C, a treatment which disrupts ester but not
amide bonds (19, 20). Approximately 50% of the bound
C3, but none of the Ab, was removed from the captured
complexes by this treatment (Fig. 2, a and b), a result repli-
cated in two additional studies with Ab 1–40 and 1–42.
The formation of covalent complexes of Ab with C3 acti-
vation products was also independently demonstrated using a
Western blotting approach. In these studies, aggregated Ab
1–40 was incubated with serum, and the complexes of insol-
uble fibrillar Ab with C3 activation fragments were then
sedimented, washed, and incubated with either 1 M hy-
droxylamine at pH 9.5 or control buffers. After washing, a
prominent band with a molecular mass of z180 kD, the
molecular mass of C3, as well as several higher molecular
mass bands, were detected with Ab to C3 (Fig. 2 c). After
stripping, the same bands were also found to react with Ab
to Ab, although the gels were darker due to the presence of
large amounts of aggregated Ab (Fig. 2 c). Bands of the same
molecular masses reactive with Abs to both Ab and C3
were also observed when the blotting studies were per-
formed in the reverse direction, i.e., blotting first with ei-
ther mAb or polyclonal Ab to Ab followed, after stripping,
by blotting with rabbit Ab or mAb to C3 (not shown). The
180-kD band and the larger bands, which contain both C3
and Ab, undoubtedly represent complexes of Ab mono-
mers with C3b monomers and oligomers, since they were
not evident in the reactions carried out in the presence of
EDTA or in the absence of fibrillar Ab (Fig. 2 c).
C3 was also detected in the large Ab aggregates on the
top of the gels (except for the EDTA lane) on longer expo-
sure (not shown). The lesser reactivity of C3 in the larger
Ab aggregates at the top of the gels, compared with the C3
monomers and oligomers within the gels, indicates that not
all Ab monomers bear a molecule of C3b; this is not sur-
prising, since Ab is in large aggregates and, in addition, in
molar excess over C3. It may also be that Ab molecules
bearing covalently bound C3b dissociate from the aggre-
gates, in analogy to the dissociation of immune complexes
by the covalent binding of C3b (21, 22).
Hydroxylamine treatment disrupted approximately half of
the complexes (Fig. 2 c). Quantitative scanning of the C3
Western blot showed that the treatment with 1 M hydrox-
ylamine at pH 9.5 removed 42% of the bound C3 com-
pared with the pH 9.5 control; the pH 9.5 buffer treatment
removed only trivial amounts (5.1%) of the bound C3 com-
pared with the pH 7.4 treatment. The Ab Western blot
could not be satisfactorily scanned due to the large back-
ground, but visual inspection reveals the same pattern (Fig.
2 c). Identical results were obtained with Ab 1–42 (not
shown). These two independent assay systems both show
that ester bonds, in part, mediate covalent attachment of C3
activation fragments to Ab. Ab 1–42 contains two serines,
at positions 8 and 26, and a tyrosine, at position 10, which
could mediate ester linkages with C3 activation fragments.
With regard to the bond(s) responsible for the nonester-
linked Ab–C3b/iC3b complexes, Ab alone has been re-
ported to generate free radicals (23) upon incubation in
aqueous solution, and oxidative processes have been associ-
ated with Ab denaturation, fragmentation, and oxidation
(24, 25). Because of the potential relevance of these pro-435 Bradt et al.
cesses to the formation of complexes of Ab with C3 activa-
tion fragments, Ab 1–42 was assessed by MALDI mass
spectroscopy after aging from 0 to 10 d. Aggregates are not
detected in these assays, since the samples are dissolved in
70% formic acid for mass spectroscopic analysis. The mo-
lecular mass of the major peak in the various samples
ranged from 4510 to 4514, and no other peaks were
present, ruling out significant oxidation, fragmentation, and
covalent cross-linking of Ab. To determine whether oxi-
dative processes mediated the formation of complexes of
Ab with C3 activation fragments, complement activation
was carried out in the presence of deferoxamine, glu-
tathione, dimethylthiourea, catalase, SOD, and catalase plus
SOD. Since none of these antioxidants or free radical scav-
engers inhibited the formation of or interfered with the de-
tection of complexes (Fig. 2 d), it is unlikely that free radi-
cal–mediated or oxidative processes are involved in the
formation of complexes of Ab with C3 activation frag-
ments. In all likelihood, amide bonds are responsible for
the remaining Ab–C3b/iC3b complexes. Ab 1–42 con-
tains two lysine residues, at positions 16 and 28, which
could mediate such linkages.
Additional studies showed that Ab triggered activation of
the terminal, proinflammatory portion of the complement-
reaction sequence in NHS. C5a, a cytokine-like activation
cleavage product of C5 with numerous biological properties,
was efficiently generated by aggregated Ab 1–42 in NHS, as
determined by a specific radioimmunoassay which detects
C5a and C5a des-Arg (lacking the COOH-terminal argi-
nine residue) (reference 26; Fig. 3 a). A sandwich ELISA in
which an mAb to a C5b-9 neoantigen located in poly C9
served as the capture Ab, and polyclonal Ab to C6 served
as the detection Ab, showed that Ab-mediated comple-
ment activation led to formation of the C5b-9 complex
(Fig. 3 b). This ELISA detects C5b-9 as well as SC5b-9
complexes; the latter are formed in NHS in the absence of
cells, as a consequence of the binding of S protein, a com-
plement control protein, to the complex. Ab 1–42 was
generally more efficient in generating C5b-9 than Ab 1–40
(Fig. 3 b). In contrast, another group recently reported that
Ab-mediated complement activation does not lead to gen-
eration of the C5b-9 complex (10). The reason(s) for their
failure to demonstrate C5b-9 formation is not known. One
possibility is the well-known variability in the properties of
different Ab preparations. In this regard, we have observed
more variability in the ability of various Ab 1–40 and Ab
1–42 preparations to trigger C5b-9 complex formation,
than in their ability to generate Ab–C3b and Ab–iC3b
complexes. Other explanations could lie in slight differ-
ences in experimental conditions. For example, their C5b-9
formation experiments were carried out in NHS diluted
1:10 in phosphate-buffered NaCl; this combination provides
suboptimal concentrations of calcium and magnesium,
which are required for CCP and ACP activation. In this
regard, we obtained 10-fold higher levels of SC5b-9 for-
mation than they obtained with 1 mM aggregated IgG in
their control studies (not shown).
The C5b-9 complex generated by Ab 1–42-mediated
complement activation was able to insert into the mem-
branes of NT2 cells, a committed neuronal precursor cell
line, when such cells were included in reaction mixtures
with aggregated Ab and NHS (Fig. 4 a). Depicted are flow
cytometric analyses with rabbit Ab to activation-specific
neoantigens in the C5b-9 MAC. C5b-9 membrane inser-
tion was likely proportional to the extent of complement
activation, since it was dependent on the concentration of
Ab 1–42. mAb to C5b-9 neoantigens gave the same result
(not shown). Identical Ab 1–40 concentrations mediated
lower levels of C5b-9 membrane insertion (not shown),
probably because of the significantly lower levels of C5b-9
formation with Ab 1–40. NT2 cells and other neuronal
cell lines are resistant to complement-dependent cytolysis,
Figure 2. Assessment of bonds mediating binding of Ab to C3 activation fragments. (a) Preaggregated Ab 1–42 (25 mM) was incubated in NHS, and
complexes were captured on 10D5-coated wells; NHS only does not contain Ab. Replicate samples were treated with pH 9.5 buffer, or with the same
buffer containing 1 M hydroxylamine (NH2OH), and remaining bound C3 was then detected and quantitated as described in Materials and Methods.
The control containing Ab, NHS, and EDTA has been subtracted. (b) Replicate wells subjected to treatment with the pH 9.5 buffer or hydroxylamine
were evaluated for residual bound Ab as described in Materials and Methods. (c) Preaggregated Ab 1–40 was incubated in NHS in the presence or ab-
sence of EDTA; lane 5 contains NHS but no Ab. After centrifugation and washing, fibrillar Ab pellets were incubated with pH 7.4 buffer (lanes 1 and 2),
pH 9.5 buffer (lane 3), or 1 M hydroxylamine in pH 9.5 buffer (lane 4). After further washing, samples were subjected to SDS-PAGE under nonreducing
conditions followed by blotting for the presence of C3 and, after stripping, for Ab. Arrow, The C3 band at z180 kD. (d) Preaggregated Ab 1–42 (50
mM) was incubated in NHS alone, and in the presence of deferoxamine (Defer.; 1 mM), glutathione (Glut.; 1 mM), dimethylthiourea (DMTU; 30 mM),
catalase (CAT; 2 3 104 U/ml), SOD (10 mM), or catalase plus SOD, and the Ab complexes with C3 activation fragments were then detected as de-
scribed in Materials and Methods.436 Complement and Alzheimer’s Disease
likely because of the presence of CD59 (27), a complement
regulatory protein, a finding confirmed here. Nevertheless,
C5b-9 insertion into NT2 cell membranes mediated an in-
crease in the permeability of the cells to propidium iodide
that was dependent on the concentration of Ab 1–42 (Fig.
4 b). These data indicate that C5b-9 generated by Ab-medi-
ated complement activation is functionally competent,
since it inserts into the membranes of neuronal precursor
cells and renders them permeable to small molecules.
Thus, Ab directly and independently activates the ACP
as well as the CCP, leading to the formation of covalent
Ab–C3b and Ab–iC3b complexes; generates C5a; and me-
diates assembly of functionally active C5b-9 complexes in
vitro. These findings have potential implications for under-
standing the mechanisms which lead to continuing neu-
ronal damage and altered glial functions in the vicinity of
NP, and thus to the progression of AD. First, they provide
an explanation for the association of bound C3 with Ab in
NP (1–3), since covalently bound C3b molecules in NP
would remain bound and provide a nidus for chronic com-
plement activation. Second, C5a generated by Ab-medi-
ated complement activation could be responsible for the
increased numbers of activated astrocytes and microglia
around NP compared with diffuse Ab plaques (28), since
these cells possess C5a receptors and are activated and mi-
grate in response to C5a (6, 29–31). C5a could also trigger
the release of proinflammatory cytokines (IL-1, IL-6, IL-8,
and TNF-a) from glial cells, as it does from other cell types
(26, 32); proinflammatory cytokines are increased in the
AD brain (2, 28, 33). These cytokines could further acti-
vate glial cells and alter neuronal and glial functions (28,
32). Third, incoming activated glial cells could bind and
remain adherent, via their complement receptors, to C3
activation fragments attached to Ab (6). Fourth, C5b-9 in-
sertion into cell membranes provides an explanation for the
association of this complex with dystrophic neurites in NP
(2, 3). Although not likely to be directly cytotoxic for neu-
rons, since they bear CD59 (6, 34), C5b-9 as well as C5b-7
and C5b-8 complexes could alter neuronal functional
properties over time by chronic low-level triggering of var-
ious cellular signaling pathways (35). If this inflammation-
based scenario is verified, complement inhibitors should be
evaluated for use in AD. Such inhibitors would need to
pass the blood–brain barrier, target both complement acti-
vation pathways, and prevent C5b-9 activation.
Figure 4. C5b-9 generated by Ab 1–42-mediated
complement activation is functionally active. (a) NT2
cells were incubated with preaggregated Ab 1–42 at
the designated concentrations in NHS, or in NHS
containing 10 mM EDTA; serum only lacks Ab. Flow
cytometric analyses with a rabbit Ab to C5b-9 neoanti-
gens are shown. Numbers (right), Percentage of C5b-91
cells, as determined by their relationship to the marker
(arrow, dashed line). (b) Density plot analyses of propid-
ium iodide and C5b-9 (FITC C5b-9) reactivities are
shown. For clarity, only live cells are depicted.
Figure 3. Ab-mediated complement activation gener-
ates C5a and the MAC. (a) Preaggregated Ab 1–42 was in-
cubated in NHS, and C5a generation was then quantitated
as described in Materials and Methods. (b) C5b-9 was quan-
titated after NHS was incubated with varying concentra-
tions of preaggregated Ab 1–42 or 1–40. SC5b-9 formation
was quantitated as described in Materials and Methods.437 Bradt et al.
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